There are another four FDA-approved drugs: dacomitinib (which targets mutant EGFR in lung cancer), neratinib (which targets ErbB2 in HER2-positive lung cancer), osimertinib (which targets EGFR T970M mutants in NSCLC), and ibrutinib (which targets BTK in mantle cell lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, and chronic graft vs. host. Here, BTK is linked to lung carcinoma.